Anixa Biosciences Inc (ANIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has a cash flow conversion efficiency ratio of -0.132x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($13.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Anixa Biosciences Inc to measure how much of total assets are equity-financed.
Anixa Biosciences Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Anixa Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Anixa Biosciences Inc to evaluate the quality of earnings relative to operating cash generation.
Anixa Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anixa Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MaxCyte Inc
NASDAQ:MXCT
|
-0.041x |
|
Daehan Synthet
KO:003830
|
-0.005x |
|
Jaeyoung Solutec Co. Ltd
KQ:049630
|
0.101x |
|
Western Energy Services Corp.
TO:WRG
|
0.027x |
|
Tambun Indah Land Bhd
KLSE:5191
|
0.005x |
|
DY Power Corp
KO:210540
|
0.044x |
|
Easy Field
TWO:6425
|
0.074x |
|
Hanjin Heavy Ind & Const Holdings Co Ltd
KO:003480
|
0.039x |
Annual Cash Flow Conversion Efficiency for Anixa Biosciences Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Anixa Biosciences Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see ANIX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $13.95 Million | $-7.17 Million | -0.514x | -32.41% |
| 2024-10-31 | $18.89 Million | $-7.33 Million | -0.388x | -46.17% |
| 2023-10-31 | $23.37 Million | $-6.21 Million | -0.266x | -15.40% |
| 2022-10-31 | $28.20 Million | $-6.49 Million | -0.230x | -62.09% |
| 2021-10-31 | $34.77 Million | $-4.94 Million | -0.142x | +80.99% |
| 2020-10-31 | $8.26 Million | $-6.18 Million | -0.747x | +24.16% |
| 2019-10-31 | $4.81 Million | $-4.74 Million | -0.985x | -19.51% |
| 2018-10-31 | $5.18 Million | $-4.27 Million | -0.824x | -72.04% |
| 2017-10-31 | $7.92 Million | $-3.80 Million | -0.479x | +86.01% |
| 2016-10-31 | $987.48K | $-3.38 Million | -3.425x | -1369.40% |
| 2015-10-31 | $5.05 Million | $1.36 Million | 0.270x | +145.46% |
| 2014-10-31 | $4.01 Million | $-2.38 Million | -0.593x | -161.83% |
| 2013-10-31 | $-3.32 Million | $-3.19 Million | 0.960x | -63.51% |
| 2012-10-31 | $-1.19 Million | $-3.14 Million | 2.630x | +488.68% |
| 2011-10-31 | $1.06 Million | $-716.00K | -0.677x | -29.28% |
| 2010-10-31 | $4.60 Million | $-2.41 Million | -0.523x | +6.83% |
| 2009-10-31 | $4.45 Million | $-2.50 Million | -0.562x | -7.80% |
| 2008-10-31 | $1.73 Million | $-901.87K | -0.521x | +74.09% |
| 2007-10-31 | $1.19 Million | $-2.40 Million | -2.012x | -39.62% |
| 2006-10-31 | $1.28 Million | $-1.85 Million | -1.441x | +6.35% |
| 2005-10-31 | $1.12 Million | $-1.72 Million | -1.539x | -139.14% |
| 2004-10-31 | $1.87 Million | $-1.21 Million | -0.643x | -33.47% |
| 2003-10-31 | $1.99 Million | $-958.50K | -0.482x | -158.94% |
| 2002-10-31 | $2.32 Million | $-431.47K | -0.186x | -8.06% |
| 2001-10-31 | $4.17 Million | $-717.85K | -0.172x | +80.22% |
| 2000-10-31 | $5.56 Million | $-4.84 Million | -0.871x | +10.05% |
| 1999-10-31 | $6.30 Million | $-6.10 Million | -0.968x | -49.64% |
| 1998-10-31 | $11.90 Million | $-7.70 Million | -0.647x | -19.26% |
| 1997-10-31 | $18.80 Million | $-10.20 Million | -0.543x | -194.53% |
| 1996-10-31 | $22.80 Million | $-4.20 Million | -0.184x | +40.29% |
| 1995-10-31 | $9.40 Million | $-2.90 Million | -0.309x | +45.15% |
| 1994-10-31 | $6.40 Million | $-3.60 Million | -0.563x | -77.40% |
| 1993-10-31 | $8.20 Million | $-2.60 Million | -0.317x | +23.53% |
| 1992-10-31 | $4.10 Million | $-1.70 Million | -0.415x | -45.12% |
| 1991-10-31 | $4.20 Million | $-1.20 Million | -0.286x | -6.49% |
| 1990-10-31 | $4.10 Million | $-1.10 Million | -0.268x | -10.00% |
| 1989-10-31 | $4.10 Million | $-1.00 Million | -0.244x | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more